In vitro cell experiments have shown that ARID1A-deficient breast cancer cells have increased sensitivity to PI3K inhibitors (Buparlisib) and AKT inhibitors (MK-2206 and Perifosine) (Samartzis et al. 2014). Here, ARID1A is linked to breast carcinoma.